Two groups of four tumour-free mice were injected with [177Lu]Lu-3 (0.335?mmol?kg?1, ca. effective in these tumour models. This first-in-class ADC holds promise for a broader applicability of ADCs across patient populations. Introduction Antibody-drug conjugates (ADCs) are a promising class of biopharmaceuticals that combine the target-specificity of monoclonal antibodies (mAbs) or mAb fragments with the potency … Continue reading Two groups of four tumour-free mice were injected with [177Lu]Lu-3 (0